A Phase III Randomized Study Comparing Busulfan – Total Body Irradiation Versus Cyclophosphamide – Total Body Irradiation Preparative Regimen in Patients with Advanced Myelodysplastic Syndrome (MDS) or MDS – Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study)

Closed

Phase

Accrual

Abbreviated Title

Advanced MDS / MDS-Related AML

Activated

06/15/2000

Closed

10/15/2001

Participants

Limited Institutions: SWOG Approved Autologous BMT Facilities

Research committees

Leukemia

Treatment

Cyclophosphamide Busulfan Radiation Therapy

Eligibility Criteria Expand/Collapse

Diagnosis of MDS or MDS-related AML subclassifiable according to the criteria in Sections 4.0 and 5.1 of the protocol; previously untreated for MDS or MDS-related AML; patients must be between the ages of 16-55; Zubrod PS 0-2, must have a genotypically HLA-identical matched sibling (at least 4 major antigen matches) and be HIV negative.

Other Clinical Trials

SWOG Clinical Trial Number

CTSU/A042001

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Research Committee(s)

Leukemia

Activated

02/27/2023

Open

Phase

SWOG Clinical Trial Number

S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

Research Committee(s)

Leukemia

Lymphoma

Symptom Control and Quality of Life

Activated

12/14/2020

Accrual

49%

Open

Phase

SWOG Clinical Trial Number

CTSU/AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

Research Committee(s)

Leukemia

Activated

12/04/2020

Open